CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Clinical Trials
Original article

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

ST-920Positive
AI Analysis

Summary

PTC Therapeutics completed its acquisition of ST-920, a BLA-stage gene therapy for Fabry Disease from Sangamo Therapeutics. BLA submission is expected in Q4 2026.

Outcome Details

Acquisition completed

Importance:7/10
Sentiment:
0.60
acquisitiongene therapyBLA submissionFabry Diseaserare disease
Related Companies

Read the original article

Published by PR Newswire Clinical Trials on September 21, 2026 8:30 PM

Read Original